409 related articles for article (PubMed ID: 17258937)
1. An update on the search for a Plasmodium vivax vaccine.
Herrera S; Corradin G; Arévalo-Herrera M
Trends Parasitol; 2007 Mar; 23(3):122-8. PubMed ID: 17258937
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
3. Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-119 on the innate immune response.
Bueno LL; Fujiwara RT; Soares IS; Braga EM
Vaccine; 2008 Feb; 26(9):1204-13. PubMed ID: 18242795
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium vivax malaria vaccine development.
Arévalo-Herrera M; Herrera S
Mol Immunol; 2001 Dec; 38(6):443-55. PubMed ID: 11741694
[TBL] [Abstract][Full Text] [Related]
5. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1.
Rodrigues MH; Rodrigues KM; Oliveira TR; Cômodo AN; Rodrigues MM; Kocken CH; Thomas AW; Soares IS
Int J Parasitol; 2005 Feb; 35(2):185-92. PubMed ID: 15710439
[TBL] [Abstract][Full Text] [Related]
6. Platform for Plasmodium vivax vaccine discovery and development.
Valencia SH; Rodríguez DC; Acero DL; Ocampo V; Arévalo-Herrera M
Mem Inst Oswaldo Cruz; 2011 Aug; 106 Suppl 1(Suppl 1):179-92. PubMed ID: 21881773
[TBL] [Abstract][Full Text] [Related]
7. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
[TBL] [Abstract][Full Text] [Related]
8. Plasmodium vivax merozoite surface protein 8 cloning, expression, and characterisation.
Perez-Leal O; Sierra AY; Barrero CA; Moncada C; Martinez P; Cortes J; Lopez Y; Torres E; Salazar LM; Patarroyo MA
Biochem Biophys Res Commun; 2004 Nov; 324(4):1393-9. PubMed ID: 15504368
[TBL] [Abstract][Full Text] [Related]
9. Vaccination for vivax malaria: targeting the invaders.
Polley SD; McRobert L; Sutherland CJ
Trends Parasitol; 2004 Mar; 20(3):99-102. PubMed ID: 16676415
[TBL] [Abstract][Full Text] [Related]
10. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
[TBL] [Abstract][Full Text] [Related]
11. Overview: immunology of malaria and progress in malaria vaccine development.
Tharavanij S
Southeast Asian J Trop Med Public Health; 1992 Sep; 23 Suppl 4():71-87. PubMed ID: 1364871
[No Abstract] [Full Text] [Related]
12. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
Giraldo MA; Arevalo-Pinzon G; Rojas-Caraballo J; Mongui A; Rodriguez R; Patarroyo MA
Vaccine; 2009 Dec; 28(1):7-13. PubMed ID: 19782110
[TBL] [Abstract][Full Text] [Related]
13. Current status of Plasmodium vivax vaccine.
Arévalo-Herrera M; Chitnis C; Herrera S
Hum Vaccin; 2010 Jan; 6(1):124-32. PubMed ID: 20009526
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation.
Igonet S; Vulliez-Le Normand B; Faure G; Riottot MM; Kocken CH; Thomas AW; Bentley GA
J Mol Biol; 2007 Mar; 366(5):1523-37. PubMed ID: 17229439
[TBL] [Abstract][Full Text] [Related]
15. Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax.
Levitus G; del Portillo HA
Mem Inst Oswaldo Cruz; 1994; 89 Suppl 2():81-4. PubMed ID: 7565138
[No Abstract] [Full Text] [Related]
16. Identification and characterisation of the Plasmodium vivax rhoptry-associated protein 2.
Patarroyo MA; Perez-Leal O; Lopez Y; Cortes J; Rojas-Caraballo J; Gomez A; Moncada C; Rosas J; Patarroyo ME
Biochem Biophys Res Commun; 2005 Nov; 337(3):853-9. PubMed ID: 16214111
[TBL] [Abstract][Full Text] [Related]
17. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.
Bell BA; Wood JF; Bansal R; Ragab H; Cargo J; Washington MA; Wood CL; Ware LA; Ockenhouse CF; Yadava A
Vaccine; 2009 Feb; 27(9):1448-53. PubMed ID: 19138714
[TBL] [Abstract][Full Text] [Related]
18. [Malaria vaccine research].
Sellioğlu B
Mikrobiyol Bul; 1986 Jan; 20(1):37-41. PubMed ID: 3523172
[TBL] [Abstract][Full Text] [Related]
19. A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.
Hostetler JB; Sharma S; Bartholdson SJ; Wright GJ; Fairhurst RM; Rayner JC
PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004264. PubMed ID: 26701602
[TBL] [Abstract][Full Text] [Related]
20. Clinical expression and antigenic profiles of a Plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7).
Cheng CW; Jongwutiwes S; Putaporntip C; Jackson AP
Malar J; 2019 Jun; 18(1):197. PubMed ID: 31196098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
